drugset / Trial / NCT03917966
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC
Phase 2
Unknown
80 enrolled
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma
Timeline
- Start
- 2020-04-07
- Primary completion
- 2023-10-07
- Completion
- 2024-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Nedaplatin | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | — |